- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Novo Nordisk Partners with OpenAI to Accelerate Drug Development
The Danish pharmaceutical company aims to leverage AI across its business, from drug discovery to manufacturing and operations.
Apr. 14, 2026 at 7:04am
Got story updates? Submit your updates here. ›
Novo Nordisk's partnership with OpenAI aims to leverage AI to streamline drug development and operations, as the company seeks to regain ground in the competitive weight-loss drug market.Indianapolis TodayNovo Nordisk, the maker of weight-loss drugs Wegovy and Ozempic, has announced a partnership with OpenAI to deploy artificial intelligence across its business. The collaboration will use OpenAI's technology to analyze complex datasets, identify promising drug candidates, and improve efficiency in manufacturing, supply chains, distribution, and corporate operations. Novo Nordisk is seeking new ways to regain ground in the intensifying obesity-drug battle with Eli Lilly, which recently won U.S. approval for its weight-loss pill Foundayo.
Why it matters
The partnership with OpenAI is part of Novo Nordisk's strategy to leverage AI and technology to streamline its drug development process and operations, as it faces increasing competition in the lucrative weight-loss drug market. The use of AI has the potential to accelerate scientific discovery, improve global operations, and redefine the future of patient care in the pharmaceutical industry.
The details
Novo Nordisk said the partnership with OpenAI will use the company's technology to analyze complex datasets, identify promising drug candidates, and improve efficiency in manufacturing, supply chains, distribution, and corporate operations. The collaboration will include pilot programs across research and development, manufacturing, and commercial operations, with full integration planned by the end of 2026. Novo Nordisk emphasized that the aim is not to replace its scientists, but to 'supercharge' them by increasing their productivity and reducing the need for future hiring.
- Novo Nordisk announced the partnership with OpenAI on April 14, 2026.
- The company plans to have the full integration of the AI technology across its business by the end of 2026.
The players
Novo Nordisk
A Danish pharmaceutical company that is a leading manufacturer of weight-loss drugs, including Wegovy and Ozempic.
OpenAI
An artificial intelligence research company that develops advanced language models and other AI technologies.
Eli Lilly
An American pharmaceutical company that is a major competitor to Novo Nordisk in the weight-loss drug market, having recently won U.S. approval for its weight-loss pill Foundayo.
Mike Doustdar
The CEO of Novo Nordisk, who emphasized that the partnership with OpenAI is not intended to replace the company's scientists, but to 'supercharge' them and increase productivity.
Sam Altman
The CEO of OpenAI, who stated that the collaboration with Novo Nordisk will help the company accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.
What they’re saying
“The aim here is not replacing our scientists. It's about supercharging them.”
— Mike Doustdar, CEO, Novo Nordisk
“AI is reshaping industries and in life sciences, it can help people live better, longer lives. This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
— Sam Altman, CEO, OpenAI
What’s next
Novo Nordisk and OpenAI plan to begin pilot programs across research and development, manufacturing, and commercial operations, with the goal of fully integrating the AI technology across the company's business by the end of 2026.
The takeaway
Novo Nordisk's partnership with OpenAI is a strategic move to leverage AI and technology to streamline its drug development process and operations, as it faces increasing competition in the lucrative weight-loss drug market. The collaboration aims to accelerate scientific discovery, improve global operations, and redefine the future of patient care in the pharmaceutical industry.
